ADAPT-DES Finds Stent Thrombosis Rate Approximately Four Times Higher in Patients With High Platelet Reactivity, Measured by VerifyNow System

SAN DIEGO - Thursday, November 10th 2011 [ME NewsWire]

Platelet Reactivity Levels Significantly Associated with 30-Day Outcomes in the Largest Platelet Reactivity Study To Date

(BUSINESS WIRE)-- Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced that patients with high platelet reactivity, i.e. high PRU values as measured by the Accumetrics VerifyNow P2Y12 Test, exhibited an approximately four times higher rate of stent thrombosis than patients without high platelet reactivity, as seen in the ADAPT-DES registry. The 30-day results from the 8,500+ patient registry were presented today at the 2011 TCT conference in San Francisco. The VerifyNow P2Y12 Test is used to measure the level of P2Y12 receptor blockade and the antiplatelet effect of medications such as clopidogrel and prasugrel (Plavix® and Effient®).

“Stent thrombosis is a rare but catastrophic event that patients are at risk for following a stent procedure,” said Dr. Paul Teirstein, Chief of Cardiology, Scripps Clinic, La Jolla, CA. “This latest data set tells us that many of these events are attributable directly to platelet reactivity,” he added. “Platelet reactivity testing provides additional information to allow us as physicians to understand the treatment effect in our effort to reduce the risk of stent thrombosis in these patients.”

The findings from ADAPT-DES are consistent with other recent publications, including the GRAVITAS pharmacodynamic analysis1 and a 3,000+ patient meta-analysis of platelet reactivity testing2, that have demonstrated a significant association between platelet reactivity and recurrent cardiovascular events . Also just published is the 2011 ACCF/AHA/SCAI PCI guideline update3,which provides guidance on which patients to test, and treatment options for patients with high on-clopidogrel platelet reactivity.

“2011 has marked a tremendous surge in the validation of the clinical role of platelet reactivity testing,” said President and CEO of Accumetrics, Timothy I. Still. “With the inclusion of platelet function testing in four separate clinical guidelines this year, and as we enter the era of generic Plavix in the US, there is an even greater need for more information to help physicians determine the most cost-effective treatment strategies while providing the highest quality patient care."

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics’ VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual’s response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient®) and clopidogrel (Plavix®)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides valuable information to help physicians make informed treatment decisions. The VerifyNow P2Y12 Test is a whole blood assay used in the laboratory or point of care setting to measure the level of platelet P2Y12 receptor blockade. Additionally, it is indicated outside the US for evaluating the risk for recurrent events in cardiovascular patients. The VerifyNow System is used by physicians in over 700 facilities in the United States and over 70 countries worldwide where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke. For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis. Effient is a registered trademark of Eli Lilly and Company.

1Price, MJ. et al Circulation. 2011;124:1132-1137 2 Brar, S et al. J Am Coll Cardiol 2011;58:1945–54 3 Levine, GN. et al. J. Am. Coll. Cardiol.published online Nov 7, 2011

Contacts

Jakob Jakobsen

310-309-1003 (Office)

310-409-5351 (Cell)

jjakobsen@biosector2.com



Timothy I. Still

President and CEO

Accumetrics

858-404-8260

press@accumetrics.com